Associate Professor Goh Boon Cher

Head and Senior Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore Director, Investigational Medicine Unit, NUHS Adjunct Associate Professor, Cancer Science Institute of Singapore, NUS Adjunct Associate Professor, Department of Pharmacology, NUS

Dr Goh is well recognized for his work in cancer pharmacology, and highly experienced in investigating novel agents for treatment of cancer. He was trained in Internal Medicine and Medical Oncology at the National University of Singapore, and was visiting fellow at the University of Chicago Section of Hematology-Oncology and Committee on Clinical Pharmacology where he was involved in drug development and pharmacogenetics. Since his return, he has contributed much to the development of a clinical trial research infrastructure at the NCIS, one of the largest clinical research groups in Singapore, and chaired the Cancer Therapeutics Research Group, an Asia Pacific cancer research group. He has mentored many clinical oncology and pharmacology fellows, and has been awarded senior clinician scientist from the Biomedical Research Council and the National Medical Research Council since 2005. In addition, he has been competitive in research grants, having held several large government awarded research grants. Beyond cancer therapeutics, he is also interested in pharmacogenomics, and has published widely in this area as well. Internationally, he has served on advisory boards on several pharmaceutical companies in early drug development, and has served on editorial boards of important journals like the Journal of Clinical Oncology. As a responsible member of clinical research, he has also espoused principles of ethics, and served for several terms as Chairman of the Domain Specific Research Board. Currently he is Director of the Investigational Medicine Unit at the NUHS, and head of Haematology-Oncology, as well as Deputy Director of the Cancer Science Institute of Singapore.

Education and Fellowships

MBBS (S'pore), MRCP (UK), MMed (Int Med), FAMS, Fellow of the Royal College of Physicians (Edinburgh)

Selected Publications

1. Goh BC, Ratain MJ, Smith R, Bertucci D, Mani S, Vogelzang NJ, et al. Phase I study of ZD9331 using a 5-day short infusion schedule. J Clin Oncol 2001;19:1476-1484
   
2. Boon-Cher Goh, Soo-Chin Lee, Ling-Zhi Wang, Lu Fan, Jia-Yi Guo, Jatinder Lamba, Erin Schuetz, Robert Lim, Hong-Liang Lim, Ai-Bee Ong, How-Sung Lee. Explaining inter-individual variability of docetaxel pharmacokinetics and pharmacodynamics in asians through phenotyping and genotyping strategies. J Clin Oncol 2002;20:3683-3690.
3. Feng ZHAO, Celine LOKE, Sheila Clare RANKIN, Jia-Yi GUO, How Sung LEE, Tuck Seng WU, Theresa TAN, Te-Chih LIU, Wan-Liang LU, Yean-Teng LIM, Qiang ZHANG, Boon Cher GOH, Soo Chin LEE. Novel CYP2C9 genetic variants in Asians and their influence on maintenance warfarin dose. Clin Pharmacol Ther 2004;76:210.
4. Anthony T.C. Chan, Mow-Ming Hsu, Boon C. Goh, Edwin P. Hui, Tsang-Wu Liu, Michael J. Millward, Ruey-Long Hong, Jacqueline Whang-Peng, Brigette B.Y. Ma, Ka F. To, Matthias Mueser, Nadia Amellal, Xiao Lin, Alex Y. Chang. A multi-center, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005;23(15):3568-76.
   
5. Soo-Chin Lee, Swee-Siang Ng, Johannes Oldenburg, Pei-Yi Chong, Simone Rost, Jia-Yi Guo, Hui-Ling Yap, Sheila Clare Rankin, Hui-Boon Khor, Tiong-Cheng Yeo, Kheng-Siang Ng, Richie Soong, Boon-Cher Goh. Inter-ethnic variability of warfarin maintenance requirement is explained by vkorc1 genotype in an Asian population. Clin Pharmacol Ther 2006;79(3):197-205.
6. Tham LS, Goh BC, Nafziger A, Guo JY, Wang LZ, Soong R, Lee SC. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther 2006;80(4):346-455.
   
7. Wen-Son Hsieh, Ross Soo, Bee-Keow Peh, Thomas Loh, Difeng Dong, Donny Soh, Lim-Soon Wong, Simon Green, Judy Chiao, Chun-Ying Cui, Yoke-Fong Lai, Soo-Chin Lee, Benjamin Mow, Richie Soong, Manuel Salto-Tellez, Boon-Cher Goh. Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. Clin Cancer Res 2009;15(4):1435-42.
8. Chiung-Ing Wong, Tong-San Koh, Ross Soo, Septian Hartono, Choon-Hua Thng, Evelyn McKeegan, Wei-Peng Yong, Chien-Shing Chen, Soo-Chin Lee, John Wong, Robert Lim, Norita Sukri, Siew-Eng Lim, Ai-Bee Ong, Joyce Steinberg, Neeraj Gupta, Rajendra Pradhan, Rod Humerickhouse, Boon-Cher Goh. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 2009;27(28):4718.
9. BC Goh, Reddy NJ, Dandamudi U, Laubscher KH, Peckham T, Hodge JP, Suttle AB, Arumugham T, Xu Y, Xu CF, Lager J, Dar MM, Lewis LD. An Evaluation of the Drug Interaction Potential of Pazopanib, Using a Modified Cooperstown 5+1 Cocktail in Patients with Advanced Solid Tumors. Clin Pharmacol Ther 2010;88(5):652-9.